Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Operating Expenses: 2016-2024

Historic Operating Expenses for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to $251.5 million.

  • Autolus Therapeutics' Operating Expenses rose 36.74% to $92.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $325.1 million, marking a year-over-year decrease of 34.44%. This contributed to the annual value of $251.5 million for FY2024, which is 38.67% up from last year.
  • According to the latest figures from FY2024, Autolus Therapeutics' Operating Expenses is $251.5 million, which was up 38.67% from $181.4 million recorded in FY2023.
  • Autolus Therapeutics' Operating Expenses' 5-year high stood at $251.5 million during FY2024, with a 5-year trough of -$215.9 million in FY2020.
  • For the 3-year period, Autolus Therapeutics' Operating Expenses averaged around $194.1 million, with its median value being $181.4 million (2023).
  • In the last 5 years, Autolus Therapeutics' Operating Expenses dropped by 15.78% in 2020 and then spiked by 166.09% in 2021.
  • Over the past 5 years, Autolus Therapeutics' Operating Expenses (Yearly) stood at -$215.9 million in 2020, then soared by 166.09% to $142.7 million in 2021, then grew by 4.59% to $149.3 million in 2022, then increased by 21.54% to $181.4 million in 2023, then skyrocketed by 38.67% to $251.5 million in 2024.